MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

Search

Geron Corp

Chiusa

SettoreSettore sanitario

1.27 1.6

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.24

Massimo

1.3

Metriche Chiave

By Trading Economics

Entrata

3.5M

-16M

Vendite

9.4M

49M

Margine di Profitto

-33.394

Dipendenti

229

EBITDA

9.2M

-7.6M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+148.39% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

40M

810M

Apertura precedente

-0.33

Chiusura precedente

1.27

Notizie sul Sentiment di mercato

By Acuity

9%

91%

5 / 371 Classifica in Healthcare

Geron Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 ott 2025, 23:25 UTC

I principali Market Mover

Salesforce Rises on New FY30 Financial Targets

15 ott 2025, 18:52 UTC

Utili
I principali Market Mover

Prologis Shares Gain on Raised Outlook, Data Center Growth

15 ott 2025, 18:30 UTC

Acquisizioni, Fusioni, Takeovers

Constellation Software to Buy U.K.'s Tecvia Holding

15 ott 2025, 17:19 UTC

Acquisizioni, Fusioni, Takeovers

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

15 ott 2025, 17:11 UTC

Acquisizioni, Fusioni, Takeovers

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

15 ott 2025, 23:48 UTC

Discorsi di Mercato

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

15 ott 2025, 23:38 UTC

Discorsi di Mercato

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 ott 2025, 22:37 UTC

Discorsi di Mercato

Economic Stars Are Aligning for RBA -- Market Talk

15 ott 2025, 21:44 UTC

Utili

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

15 ott 2025, 20:50 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

15 ott 2025, 20:44 UTC

Acquisizioni, Fusioni, Takeovers

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

15 ott 2025, 20:44 UTC

Acquisizioni, Fusioni, Takeovers

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

15 ott 2025, 20:43 UTC

Acquisizioni, Fusioni, Takeovers

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

15 ott 2025, 20:34 UTC

Utili

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

15 ott 2025, 20:31 UTC

Acquisizioni, Fusioni, Takeovers

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

15 ott 2025, 20:17 UTC

Acquisizioni, Fusioni, Takeovers

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

15 ott 2025, 19:06 UTC

Utili

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

15 ott 2025, 19:04 UTC

Discorsi di Mercato

Oil Futures Post Back-to-Back Losses -- Market Talk

15 ott 2025, 18:46 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

15 ott 2025, 18:23 UTC

Utili

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

15 ott 2025, 17:37 UTC

Acquisizioni, Fusioni, Takeovers

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

15 ott 2025, 17:34 UTC

Discorsi di Mercato

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

15 ott 2025, 16:57 UTC

Utili

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

15 ott 2025, 16:51 UTC

Acquisizioni, Fusioni, Takeovers

EssilorLuxottica Doesn't Disclose Financial Details

15 ott 2025, 16:50 UTC

Acquisizioni, Fusioni, Takeovers

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

15 ott 2025, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

15 ott 2025, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

15 ott 2025, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

15 ott 2025, 16:47 UTC

Acquisizioni, Fusioni, Takeovers

EssilorLuxottica Buys Ikerian

15 ott 2025, 16:34 UTC

Discorsi di Mercato

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Confronto tra pari

Modifica del prezzo

Geron Corp Previsione

Obiettivo di Prezzo

By TipRanks

148.39% in crescita

Previsioni per 12 mesi

Media 3.08 USD  148.39%

Alto 5 USD

Basso 1 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Geron Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

4

Acquista

2

Mantieni

1

Vendi

Sentiment

By Acuity

5 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
help-icon Live chat